HOPEFULLY FIND A VACCINE THAT PREVENTS HIV INFECTIONS. >> WELCOME BACK. THE UNIVERSITY
OF TEXAS HEALTH SCIENCE CENTER
AT SAN ANTONIO AND CLINICAL
PARTNER UNIVERSITY HEALTH SOON
WILL BEGIN A PHASE. ONE OF THE
CLINICAL RESEARCH STUDY OF AN
HIV VACCINE, THE VACCINE WOULD
BE PRODUCED BY MODERNA AND THIS
WILL BE SAN ANTONIO’S FIRST
EVER STUDY OF IT IN OUR HIV
VACCINE. TO TALK MORE ABOUT
THIS EXCITING NEW STUDY, WE
BRING IN DOCTOR BARBARA TAYLOR
WITH UT HEALTH, SAN ANTONIO
AND UNIVERSITY HEALTH. GOOD
MORNING.
GOOD MORNING. FIRST, FIRST OFF,
DOCTOR, THERE’S BEEN SO MUCH
ATTENTION PAID TO TO COVID AS
IT AS IT SHOULD BE. BUT WE
ALMOST FORGET THAT THERE’S
OTHER THINGS GOING ON. THERE’S
OTHER STUDIES AS OTHER
DISCOVERIES.
>> THERE’S OTHER RESEARCH GOING
ON. SO GIVE US THE IDEA BEHIND
THIS PARTICULAR STUDY.
>> SO I THINK ONE OF THE VERY
EXCITING THINGS ABOUT THIS
STUDY IS IT TAKES EVERYTHING WE
HAVE LEARNED IN THE AMAZING
SCIENTIFIC BREAKTHROUGHS THAT
LED TO THE DEVELOPMENT OF THE
COVID VACCINES PARTICULAR THE
MRNA VACCINES AND USES THAT
TO ADDRESS A LONGSTANDING
CHALLENGE FOR THE SCIENTIFIC
COMMUNITY, WHICH IS THE
DEVELOPMENT OF AN HIV VACCINE.
>> AND DOCTOR TAYLOR, WHO IS A
PRIME CANDIDATE FOR THE STUDY
AND HOW MANY PEOPLE ARE BEING
ENROLLED AT THIS TIME.
SO IT IS IMPORTANT TO KNOW THAT
THIS IS A PHASE ONE STUDY.
SO IN THIS CASE, WE ARE TESTING
FOR SAFETY. AND WE’RE TESTING
FOR IMMUNE RESPONSE. THOSE
ANTIBODIES AND T CELLS THAT
WE’VE HEARD SO MUCH ABOUT IN
THE CONTEXT OF THE COVID
PANDEMIC.
>> SO WE’RE ONLY ENROLLING VERY
HEALTHY PEOPLE WHO ARE BETWEEN
18 AND 49 YEARS OF AGE. AND
WE WOULD LIKE TO ENROLL PEOPLE
WHO ARE REALLY EXCITED ABOUT
CONTRIBUTING TO A FIRST STEP
IN THE DEVELOPMENT OF AN HIV
VACCINE.
>> NOW NOT GOING TO START.
GO AHEAD. I WAS GOING TO SAY
LOCALLY, WE’D LIKE TO ENROLL 15
PARTICIPANTS IF WE CAN.
>> 15 PARTICIPANTS IN THIS
PARTICULAR STUDY. YEAH, THIS
IS AN NEW VACCINE WOULD BE
SPECIFICALLY TARGETED TO HIV.
BUT HOW DID THE COVID RESEARCH
PLAY A ROLE IN THIS PARTICULAR
STUDY?
>> SO THIS IS AN MRNA VACCINE.
AND SO AS MANY OF YOU KNOW, THE
MRNA VACCINES WERE IN
DEVELOPMENT OR THE TECHNOLOGY
HAS BEEN IN DEVELOPMENT FOR 2
DECADES. AND THAT REALLY CAME
TO FRUITION IN TERMS OF HELPING
PEOPLE WITH COVID VACCINES.
THESE ARE THE FIRST TIME WE’VE
USED MRNA VACCINES AND THEY
HAVE WORKED INCREDIBLY WELL
AND EFFECTIVELY. SO THAT’S WHAT
WE’RE USING TOO.
DEVELOP THESE VACCINES FOR HIV.
>> IF SOMEONE WANTS TO JOIN THE
STUDY, WHAT SHOULD THEY DO?
SO WE HAVE INFORMATION ABOUT
THE STUDY AT UT HEALTH RESEARCH
DOT COM, WHICH PROFILES ARE
VARIOUS CLINICAL TRIALS.
THAT HIV VACCINE TRIAL IS THE
SECOND ONE ON THE WEB SITE.
OR YOU CAN CALL 2, 1, 0, 4, 6,
9, 3, 2, 0, 6,
>> I WAS AGAIN, YOU’RE LOOKING
FOR 15 PEOPLE TO PARTICIPATE IN
THIS STUDY FOR THOSE OF US WHO
HAVE BEEN AROUND SINCE THE 80’S
BACK THEN IF YOU GOT HIV WAS
BASICALLY A DEATH SENTENCE.
THERE’S BEEN A LOT OF
TREATMENTS THAT HAVE COME ALONG
ALONG THE WAY. BUT HOW IS THIS
DIFFERENT THAN THOSE TREATMENTS
AND HOW IS THIS BASICALLY A
GAME CHANGER FOR HIV?
>> I ALSO HAVE BEEN AROUND
SINCE THE 80’S AND I HAVE BEEN
TREATING PEOPLE LIVING WITH HIV
FOR THE LAST 2 DECADES. AND
YOU’RE RIGHT. TREATMENT HAS
BEEN AN AMAZING AND HE’S BEEN
GREAT ADVANCES. NOW MY PATIENTS
CAN TAKE ONE PILL ONCE A DAY
AND LIVE A LONG AND NORMAL LIFE
SPAN. BUT WE DON’T HAVE
EFFECTIVE VACCINES FOR HIV.
THERE’S PRAK WHICH IS
PREVENTION. BUT FOR THAT, YOU
HAVE TO TAKE A PILL EVERY DAY.
SO WE ARE REALLY HOPING TO
DEVELOP A TOOL LIKE WE HAVE FOR
COVID, WHICH WE CAN GIVE PEOPLE
A SHOT OR A COUPLE OF SHOTS
AND PROTECT THEM FOR LIFE.
>> I THINK IS ABSOLUTELY
FANTASTIC. THIS STUDY IS
ACTUALLY TAKING PLACE HERE IN
SAN ANTONIO, PUTTING US ON THE
MAP, SO TO SPEAK IN IT.
>> YES, WE’RE VERY EXCITED.
WE’RE COLLABORATE SHOW UT
HEALTH AND UNIVERSITY HEALTH
ARE REALLY EXCITED TO BE
COLLABORATING WITH THE IFB AND
MODERNA ON THIS STUDY.
>> VERY EXCITING STUFF. WELL,
THANK YOU SO MUCH FOR YOUR TIME